Endo Axiom takes oral nanoparticle insulin into first-in-human trial
Australia-based Endo Axiom Pty Ltd has dosed its first human participants with an oral nanoparticle-encapsulated insulin formulation, marking the company's...
Read full article →Development
Systematic, data-driven science coverage · Sunday, September 13, 2026
Most Read
Development
Insilico’s rentosertib becomes first AI-discovered drug to enter Phase III
Business
ViaNautis expands into spinal cord injury with SCI Ventures backing for polyNaut platform
Development
Disc Medicine’s DISC-3405 reduces phlebotomy needs in Phase II polycythemia vera trial
Business
Insightec spinout Lotus Neuro launches brain drug delivery platform
Development
AbbVie's atogepant meets primary endpoint in Phase III menstrual migraine trial
Development
1d agoNeuroHarmonics launches first patient trial of non-invasive deep-brain ultrasound for essential tremor
London-based neurotechnology company NeuroHarmonics is set to begin recruiting patients for the first clinical evaluation of its non-invasive deep-brain...
Development
1d agoGan & Lee advances once-weekly oral GLP-1 peptide into Phase I
China-based Gan & Lee Pharmaceuticals Co., Ltd. has dosed the first participant in a Phase I study of GZC8072, an oral peptide glucagon-like peptide-1...
Development
2d agoOMass enters human testing with MC2R antagonist OMS1620 for congenital adrenal hyperplasia
UK-based OMass Therapeutics has registered a Phase I trial of OMS1620, an oral small-molecule melanocortin-2 receptor (MC2R) antagonist being developed for...
Development
2d agoFDA pauses enrollment in Biohaven’s opakalim trials; pivotal readout remains on track
A partial clinical hold on opakalim (BHV-7000), Biohaven Ltd.'s (NYSE: BHVN) selective Kv7.2/7.3 potassium channel activator in pivotal development for...
Development
2d agoAbbVie's atogepant meets primary endpoint in Phase III menstrual migraine trial
Atogepant (Qulipta/Aquipta) met the primary endpoint and all eight ranked secondary endpoints in the Phase III LUNA trial evaluating preventive treatment of...
Development
2d agoNodThera rebrands as Rezera as ruvonoflast meets Phase II endpoint, eyes Phase III in PAD
Ruvonoflast (NT-0796), an oral NLRP3 inflammasome inhibitor developed by Boston-based Rezera Inc. (formerly NodThera), met its primary endpoint in the...
Development
3d agoSeismic launches global Phase III trial of istaroxime in cardiogenic shock
Durham, North Carolina-based Seismic Pharmaceuticals has launched a global Phase III trial of istaroxime in cardiogenic shock, a life-threatening condition...
Development
3d agoDisc Medicine’s DISC-3405 reduces phlebotomy needs in Phase II polycythemia vera trial
Massachusetts-based Disc Medicine (Nasdaq: IRON) released Phase II data showing that DISC-3405, an anti-TMPRSS6 monoclonal antibody, sharply reduced...
Development
2d agoInsilico’s rentosertib becomes first AI-discovered drug to enter Phase III
Insilico Medicine (HKEX: 3696) has dosed the first patient in GENESIS-IPF-3, the Phase III trial of rentosertib (ISM001-055 / INS018\055) in idiopathic...
Development
2d agoBioNTech ends autogene cevumeran Phase II after OS imbalance favors control
The BNT122-01 Phase II trial of autogene cevumeran in resected colorectal cancer has been terminated after an independent data safety monitoring board...
Development
3d agoIndependent research teams validate Apeximmune's PLA2G2D target for overcoming anti-PD-1 resistance
A Nature publication has given South San Francisco-based Apeximmune Therapeutics substantial external validation, with two independent research teams...
Development
3d agoIDEAYA, Servier expand darovasertib into Phase III adjuvant uveal melanoma
San Francisco-based IDEAYA Biosciences (Nasdaq: IDYA) and France-based Servier announced that the first patient has been dosed in OptimUM-11, a global Phase...
Development
4d agoLeyden Labs advances RIG-101 after Phase I shows safety and on-target immune activation
Phase I data from Netherlands-based Leyden Laboratories B.V.'s intranasal innate immune modulator RIG-101 showed acceptable safety and on-target...
Development
4d agoPrana reports prolonged Type 2 biomarker suppression with IL-4Rα/TSLP bispecific
Phase I data from a placebo-controlled study in healthy adults suggest that PRA-216, a bispecific antibody that simultaneously blocks IL-4Rα and TSLP, can...
Development
4d agoLancet data show durable responses with PeproMene's BAFF-R CAR T after CD19 CAR T failure
Phase I data for PMB-CT01, a B-cell activating factor receptor (BAFF-R)-targeted autologous chimeric antigen receptor (CAR) T-cell therapy, have been...
The AllSci Brief
Free, systematic R&D and deal news. Daily.